Filing Flows › DataMeds AI (MEDS) › Q2 2026
DataMeds AI (MEDS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 17, 2026
DataMeds AI (MEDS) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), -77% from a year earlier and +14% from the quarter before. Operating margin was -412.7%.
DataMeds AI, Q2 2026: revenue $1.8M (-77% year over year), operating margin -412.7%, net loss $18.4M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +14% | -77% |
| Operating profit | −$7.3M | — | — |
| Net earnings | −$18.4M | — | — |
| Operating cash flow | −$2.9M | — | — |
What changed
Revenue was $1.8M in Q2 2026, down 77% year over year and up 14% from the previous quarter. Pharmacy Retail Sales was the largest line at 89% of revenue. Product lost $7.5M year over year (down 99%), 124% of the total change.
Gross margin was 10.2%, up 3.7 points from Q2 2025. Operating costs exceeded revenue by $7.3M, an operating margin of -412.7%. Operating expenses grew 25% against a revenue fall of 77%. The fastest-growing cost line was General & admin (+45%). The quarter ended with a net loss of $18.4M, wider than the previous quarter's $7.7M loss. Net interest and other expense of $11.0M was the main reason.
Operating cash flow was −$2.9M. Non-cash charges added back $357K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $13.9M.
Questions
What was DataMeds AI's revenue in the second quarter 2026?
DataMeds AI (MEDS) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), -77% from a year earlier and +14% from the quarter before.
Was DataMeds AI profitable in the second quarter 2026?
Operating loss was $7.3M (-412.7% of revenue) and net loss $18.4M.
Source: DataMeds AI 10-Q on SEC EDGAR.